-

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TELIX PHARMACEUTICALS LIMITED (TLX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On July 22, 2025, Telix disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.”

On this news, Telix’s stock price fell $1.70, or 10.4%, to close at $14.58 per share on July 23, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Telix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Industry:

Law Offices of Howard G. Smith

NASDAQ:TLX
Release Versions
English

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc....

Did You Lose Money on Everest Group, Ltd. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 11.4% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Everest Group, Ltd. ("Everest" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Everest Group, Ltd. (NYSE: EG) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 27, 2025 disclosure concerning Everest Group, Ltd.Investors with los...

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc. Investors...
Back to Newsroom